Phase 2 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who give written consent to take part in the study.
- Women between 18 and 70 years of age.
- Women of childbearing age who have a negative blood pregnancy test taken within 14 days before treatment starts, and who agree to use a contraceptive method approved by their doctor during the study and for 12 weeks after treatment ends.
- Postmenopausal women who have had both ovaries surgically removed, are aged 60 or older, or are under 60 with no periods for at least 12 months and hormone levels that confirm menopause.
- Women diagnosed with a specific stage of cervical cancer (stage IB2 to IVA), with or without nearby lymph nodes affected (as long as those nodes are smaller than 2 cm).
- Cancer confirmed by laboratory testing as one of these types: squamous carcinoma, adenosquamous carcinoma, adenocarcinoma, or glassy cell carcinoma.
- Women who have not had any previous treatment for this cancer and whose health allows them to receive the drug gemcitabine.
- Cancer that can be measured on CT or MRI scans using standard measurement guidelines.
- A general health/functioning score of 0 to 3 on the World Health Organization scale (confirm with trial site).
- Reduced kidney function meeting a specific threshold, measured by a standard kidney function formula (confirm with trial site).
- Blood counts and liver function results within acceptable ranges, including sufficient haemoglobin, white blood cells, platelets, and liver enzyme levels (a blood transfusion before treatment to reach the required haemoglobin level is permitted).
- A normal chest X-ray.
Who may not be able to join:
- People who have had or currently have another cancer, except for certain non-serious skin cancers.
- People with diabetes and/or high blood pressure that has affected the eyes or caused high levels of protein in the urine.
- People with an active tuberculosis (TB) infection.
- People living with HIV.
- People with a history of Lupus or other rheumatic diseases that have caused kidney damage.
- People who have an abnormal opening between the bladder and vagina, or between the bladder and rectum, at the time of diagnosis.
- People with other serious uncontrolled health conditions, including active infections, heart failure, unstable chest pain, irregular heartbeat, uncontrolled diabetes, very difficult to manage high blood pressure, or serious mental illness.
- People currently taking part in another experimental drug trial.
- People whose social, family, or location circumstances suggest they may have difficulty following the study requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lucely C Cetina, MD, M.Sc., National Institute of Cancerología
Phone: +5215554851237
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Glomerular Filtration Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.